This page shows the details of why an item matched the keywords from your search.
| Item Type | Name |
|
Concept
|
Lymphoma, B-Cell
|
|
Concept
|
Lymphoma, Mantle-Cell
|
|
Concept
|
Lymphoma, B-Cell, Marginal Zone
|
|
Academic Article
|
The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma.
|
|
Academic Article
|
Posttransplant lymphoproliferative disorder: extranodal marginal zone lymphoma occurring after renal transplantation.
|
|
Academic Article
|
Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
|
|
Academic Article
|
Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
|
|
Academic Article
|
Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.
|
|
Academic Article
|
GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas.
|
|
Academic Article
|
Breast implant-associated anaplastic large-cell lymphoma and the role of brentuximab vedotin (SGN-35) therapy: A case report and review of the literature.
|
|
Academic Article
|
Phase 2 study of CHOP-R-14 followed by 90Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma.
|
|
Academic Article
|
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
|
|
Academic Article
|
Parsaclisib, a PI3Kd inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study.
|